Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...